进展性多发性硬化症的个性化治疗方法：疾病修正疗法（DMTs）的现状与未来展望
A Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future Perspectives.
作者信息
D'Amico Emanuele, Patti Francesco, Zanghì Aurora, Zappia Mario
机构信息
Multiple Sclerosis Center, Policlinico G. Rodolico, via Santa Sofia, 78 Catania 95123, Italy.
出版信息
Int J Mol Sci. 2016 Oct 17;17(10):1725. doi: 10.3390/ijms17101725.
Abstract
Using the term of progressive multiple sclerosis (PMS), we considered a combined population of persons with secondary progressive MS (SPMS) and primary progressive MS (PPMS). These forms of MS cannot be challenged with efficacy by the licensed therapy. In the last years, several measures of risk estimation were developed for predicting clinical course in MS, but none is specific for the PMS forms. Personalized medicine is a therapeutic approach, based on identifying what might be the best therapy for an individual patient, taking into account the risk profile. We need to achieve more accurate estimates of useful predictors in PMS, including unconventional and qualitative markers which are not yet currently available or practicable routine diagnostics. The evaluation of an individual patient is based on the profile of disease activity.Within the neurology field, PMS is one of the fastest-moving going into the future.
摘要
使用进行性多发性硬化症（PMS）这一术语，我们纳入了继发进展型多发性硬化症（SPMS）和原发进展型多发性硬化症（PPMS）患者的综合群体。这些多发性硬化症形式无法通过获批疗法验证其疗效。在过去几年中，已开发出几种风险评估方法来预测多发性硬化症的临床病程，但没有一种方法对PMS形式具有特异性。精准医疗是一种治疗方法，基于识别对个体患者而言可能是最佳的治疗方法，同时考虑风险状况。我们需要更准确地估计PMS中有用的预测指标，包括目前尚未可用或无法实际用于常规诊断的非常规和定性标志物。对个体患者的评估基于疾病活动情况。在神经学领域，PMS是迈向未来发展最快的领域之一。
相似文献
1
A Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future Perspectives.进展性多发性硬化症的个性化治疗方法：疾病修正疗法（DMTs）的现状与未来展望
Int J Mol Sci. 2016 Oct 17;17(10):1725. doi: 10.3390/ijms17101725.
2
Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function.进展性多发性硬化症：疾病治疗、修复和功能恢复的前景。
Lancet. 2017 Apr 1;389(10076):1357-1366. doi: 10.1016/S0140-6736(16)31320-4. Epub 2016 Nov 24.
3
Disease-modifying treatments for progressive multiple sclerosis.治疗进展性多发性硬化症的疾病修正疗法。
Mult Scler. 2013 Oct;19(11):1428-36. doi: 10.1177/1352458513502572.
4
Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.多发性硬化症：现有和新兴的疾病修正治疗方法和治疗策略。
Mayo Clin Proc. 2014 Feb;89(2):225-40. doi: 10.1016/j.mayocp.2013.11.002.
5
Targets of therapy in progressive MS.进展性多发性硬化症的治疗靶点。
Mult Scler. 2017 Oct;23(12):1593-1599. doi: 10.1177/1352458517729455.
6
'Progressive MS - macro views': The need for novel clinical trial paradigms to enable drug development for progressive MS.进展型多发性硬化症 - 宏观视角：为进展型多发性硬化症开发药物需要新型临床试验范式。
Mult Scler. 2017 Oct;23(12):1649-1655. doi: 10.1177/1352458517729457.
7
The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.大麻素用于进行性炎症性脑病（CUPID）试验：一项随机双盲安慰剂对照平行组多中心试验及大麻素延缓多发性硬化症进展的经济学评估。
Health Technol Assess. 2015 Feb;19(12):vii-viii, xxv-xxxi, 1-187. doi: 10.3310/hta19120.
8
CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis.CSF 炎症和轴突损伤增加，并在进行性多发性硬化症中相关。
Mult Scler. 2013 Jun;19(7):877-84. doi: 10.1177/1352458512466929. Epub 2012 Nov 24.
9
Discontinuing disease-modifying therapy in progressive multiple sclerosis: can we stop what we have started?在进展性多发性硬化症中停用疾病修正疗法：我们能否停止我们已经开始的治疗？
Mult Scler. 2009 Dec;15(12):1528-31. doi: 10.1177/1352458509351730. Epub 2009 Dec 7.
10
Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study.原发性进行性多发性硬化症的抗炎疾病修正治疗与残疾进展：队列研究。
Eur J Neurol. 2019 Feb;26(2):363-370. doi: 10.1111/ene.13824. Epub 2018 Nov 2.
引用本文的文献
1
Evaluating Cognitive Outcomes in Multiple Sclerosis: Real-World Impact of Ozanimod on Processing Speed Using BICAMS.评估多发性硬化症的认知结果：奥扎莫德使用BICAMS对处理速度的实际影响
Neurol Ther. 2025 May 12. doi: 10.1007/s40120-025-00736-8.
2
Unraveling the inflammation-degeneration tangle in early MS: preliminary insights from ferritin, neurogranin, TREM2, and retinal ganglion cell layer.解析早期多发性硬化症中的炎症-退变纠葛：来自铁蛋白、神经颗粒蛋白、触发受体表达于髓细胞2及视网膜神经节细胞层的初步见解
J Neurol. 2025 Jan 15;272(2):109. doi: 10.1007/s00415-024-12797-0.
3
Ocrelizumab Extended Interval Dosing in Primary Progressive Multiple Sclerosis: An Italian Experience.奥瑞珠单抗延长间隔给药治疗原发性进行性多发性硬化症：意大利经验。
Curr Neuropharmacol. 2024;22(2):339-345. doi: 10.2174/1570159X22666231002142709.
4
Editorial: Immunosenescence and multiple sclerosis: Prognostic and therapeutic implications.社论：免疫衰老与多发性硬化症：预后及治疗意义
Front Neurol. 2022 Aug 30;13:996342. doi: 10.3389/fneur.2022.996342. eCollection 2022.
5
Brain Structural and Functional Alterations in Multiple Sclerosis-Related Fatigue: A Systematic Review.多发性硬化相关疲劳中的脑结构和功能改变：一项系统综述
Neurol Int. 2022 Jun 8;14(2):506-535. doi: 10.3390/neurolint14020042.
6
Stopping Interferon Beta 1b Does Not Influence the Risk of Disability Accrual in Non-Active SPMS: Results from an Italian Real-World Study.停止干扰素 β-1b 治疗不会影响非活跃型 SPMS 残疾累积风险：来自意大利真实世界研究的结果。
Int J Environ Res Public Health. 2022 May 17;19(10):6069. doi: 10.3390/ijerph19106069.
7
Mesenchymal Stem Cell-Derived Extracellular Vesicles and Their Therapeutic Use in Central Nervous System Demyelinating Disorders.间质干细胞衍生的细胞外囊泡及其在中枢神经系统脱髓鞘疾病中的治疗应用。
Int J Mol Sci. 2022 Mar 30;23(7):3829. doi: 10.3390/ijms23073829.
8
Vitamin D and Depressive Symptoms in Adults with Multiple Sclerosis: A Scoping Review.维生素 D 与多发性硬化症成人抑郁症状：范围综述。
Int J Environ Res Public Health. 2021 Dec 25;19(1):199. doi: 10.3390/ijerph19010199.
9
Association between multiple sclerosis and dietary patterns based on the traditional concept of food nature: a case-control study in Iran.基于食物自然属性传统观念的饮食模式与多发性硬化症的相关性：伊朗的一项病例对照研究。
BMC Neurol. 2021 Nov 18;21(1):453. doi: 10.1186/s12883-021-02483-3.
10
Personalizing Medicine and Technologies to Address the Experiences and Needs of People with Multiple Sclerosis.个性化医疗与技术，以满足多发性硬化症患者的体验和需求。
J Pers Med. 2021 Aug 12;11(8):791. doi: 10.3390/jpm11080791.
本文引用的文献
1
Absence of systemic oxidative stress and increased CSF prostaglandin F2α in progressive MS.进展性多发性硬化症患者无系统性氧化应激和脑脊液前列腺素 F2α 增加。
Neurol Neuroimmunol Neuroinflamm. 2016 Jun 30;3(4):e256. doi: 10.1212/NXI.0000000000000256. eCollection 2016 Aug.
2
Circulating microRNAs as biomarkers in progressive multiple sclerosis.循环 microRNAs 作为进展性多发性硬化症的生物标志物。
Mult Scler. 2017 Mar;23(3):403-412. doi: 10.1177/1352458516651141. Epub 2016 Jul 11.
3
MicroRNAs associated with the pathogenesis of multiple sclerosis.与多发性硬化症发病机制相关的微小RNA
J Neuroimmunol. 2016 Jun 15;295-296:148-61. doi: 10.1016/j.jneuroim.2016.04.014. Epub 2016 Apr 27.
4
Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis.进展性多发性硬化症的治疗进展与未来前景。
Neurotherapeutics. 2016 Jan;13(1):58-69. doi: 10.1007/s13311-015-0409-z.
5
Stem cell therapy in multiple sclerosis: a future perspective.干细胞疗法治疗多发性硬化症：未来展望。
Neurodegener Dis Manag. 2015;5(3):167-70. doi: 10.2217/nmt.15.6.
6
The crucial role of mast cells in blood-brain barrier alterations.肥大细胞在血脑屏障改变中的关键作用。
Exp Cell Res. 2015 Oct 15;338(1):119-25. doi: 10.1016/j.yexcr.2015.05.013. Epub 2015 May 21.
7
Neuroprotection for acute optic neuritis-Can it work?急性视神经炎的神经保护——它能起作用吗？
Mult Scler Relat Disord. 2013 Oct;2(4):307-11. doi: 10.1016/j.msard.2013.02.001. Epub 2013 Mar 13.
8
High doses of biotin in chronic progressive multiple sclerosis: a pilot study.高剂量生物素治疗慢性进行性多发性硬化症：一项试点研究。
Mult Scler Relat Disord. 2015 Mar;4(2):159-69. doi: 10.1016/j.msard.2015.01.005. Epub 2015 Jan 24.
9
Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives.进展性多发性硬化症的临床试验：经验教训与未来展望。
Lancet Neurol. 2015 Feb;14(2):208-23. doi: 10.1016/S1474-4422(14)70264-9.
10
Pathological mechanisms in progressive multiple sclerosis.进行性多发性硬化症的病理机制。
Lancet Neurol. 2015 Feb;14(2):183-93. doi: 10.1016/S1474-4422(14)70256-X.
Zotero 插件